The administration of exogenous erythropoietin has been occasionally helpful for MMM-associated anemia. Rodriguez et al.28 described their experience and conducted a meta-analysis of patients with MMM treated with erythropoietin. A response rate of 33% was seen, with doses of up to 600 units/kg/week being required. Patients with serum erythropoietin levels of <125 mU/mL had the highest likelihood of response. Responses to exogenous erythropoietin most frequently occurred within 2-3 months, with responses ranging from mild decreases in transfusion dependence to complete transfusion independence.
Was this article helpful?